Publication Name	World Journal of Gastroenterology
Manuscript ID	19183
Country	Japan

Received	2015-04-29 18:53
Peer-Review Started	2015-05-08 10:19
To Make the First Decision	2015-08-31 09:15
Return for Revision	2015-09-01 19:38
Revised	2015-09-05 10:04
Second Decision	2015-10-14 09:00
Accepted by Journal Editor-in-Chief	2015-10-14 18:03
Accepted by Company Editor-in-Chief	2015-10-26 17:44
Articles in Press	2015-10-26 17:44
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-11-03 09:12
Publish the Manuscript Online	2015-11-18 12:39

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Topic Highlights
Article Title	Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer
Manuscript Source	Invited Manuscript
All Author List	Ken-ichi Fujita, Yutaro Kubota, Hiroo Ishida and Yasutsuna Sasaki
Funding Agency and Grant Number
Corresponding Author	Ken-ichi Fujita, PhD, Professor, Institute of Molecular Oncology, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 1428555, Japan. k.fujita@med.showa-u.ac.jp
Key Words	Irinotecan; Metastatic colorectal cancer; Survival advantage; Personalized chemotherapy; Dosing; Severe renal failure
Core Tip	Irinotecan is a key anticancer drug for the treatment of metastatic colorectal cancer. By combining irinotecan with 5-fluorouracil, oxaliplatin, and a molecularly-targeted drug, overall survival of longer than 30 mo has been achieved. Exposure to SN-38, the active metabolite of irinotecan, shows large inter- and intra-patient variability and can cause severe irinotecan-related toxicities. Many studies have recommended the dose reduction of irinotecan for patients with UDP-glucuronosyltransferase 1A1 polymorphisms and liver dysfunction. Surprisingly, dose reduction may be required in patients with severe renal failure, even though irinotecan is predominantly eliminated via the liver.
Publish Date	2015-11-18 12:39
Citation	Fujita K, Kubota Y, Ishida H, Sasaki Y. Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer. World J Gastroenterol 2015; 21(43): 12234-12248
URL	http://www.wjgnet.com/1007-9327/full/v21/i43/12234.htm
DOI	http://dx.doi.org/10.3748/wjg.v21.i43.12234

Full Article (PDF)	WJG-21-12234.pdf
Full Article (Word)	WJG-21-12234.doc
Manuscript File	19183-Review.docx
Answering Reviewers	19183-Answering reviewers.pdf
Audio Core Tip	19183-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	19183-Conflict-of-interest statement.pdf
Copyright License Agreement	19183-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	19183-Language certificate.pdf
Peer-review Report	19183-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	19183-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	19183-Scientific misconduct check.pdf
Scientific Editor Work List	19183-Scientific editor work list.pdf